Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80 / IL-2 in patients with metastatic renal cell carcinoma - Buchner, A; Pohla, H; Willimsky, G (Hum Gene Ther, 2010)
et al.